Palvella Therapeutics (PVLA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting conducted virtually to maximize stockholder participation and accessibility.
Agenda and rules of conduct were adopted and made available on the virtual meeting site.
Chairman, board members, and independent auditor were introduced; meeting officially called to order.
Board and executive committee updates
Quorum confirmed with proxies representing a majority of voting power received.
Notice of meeting and proxy materials were distributed to stockholders of record.
Shareholder proposals
Six proposals presented: election of three Class III directors, ratification of auditor, advisory vote on executive compensation, advisory vote on frequency of compensation votes, amendment to equity plan, and potential adjournment.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Palvella Therapeutics
- QTORIN platform advances rare skin disease therapies, targeting multi-billion dollar orphan markets.PVLA
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Positive Phase 3 data and $230M financing drive NDA submission and launch readiness in 2027.PVLA
Q1 20267 May 2026 - Key votes include director elections, auditor ratification, and an equity plan share increase.PVLA
Proxy filing30 Apr 2026 - Board recommends all proxy proposals, highlighting governance, compensation, and equity plan changes.PVLA
Proxy filing30 Apr 2026 - QTORIN rapamycin showed strong efficacy and safety in Phase 3 SELVA for microcystic LMs.PVLA
Study result13 Apr 2026 - Positive Phase III data, pipeline growth, and $230M financing support 2026–27 milestones.PVLA
Q4 20256 Apr 2026 - QTORIN™ rapamycin achieved strong Phase 3 results in mLM, targeting a multi-billion dollar rare disease market.PVLA
Corporate presentation2 Apr 2026 - Merger forms a Nasdaq-listed rare disease biopharma with $80.5M cash and late-stage assets.PVLA
M&A Announcement3 Feb 2026 - Up to $300M in securities to advance rare skin disease therapies, backed by positive clinical data.PVLA
Registration Filing3 Jan 2026